This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cogan, J. J. Articles by Rapaport, E. Search for Related Content PubMed PubMed Citation Articles by Cogan, J. J. Articles by Rapaport, E.

Circulation, Vol 61, 316-323, Copyright © 1980 by American Heart Association

ARTICLES

Renal effects of nitroprusside and hydralazine in patients with congestive heart failure

JJ Cogan, MH Humphreys, CJ Carlson and E Rapaport

The acute effects of nitroprusside infusion and intravenous hydralazine on renal hemodynamics and function were evaluated in nine male patients with severe, low cardiac output, congestive heart failure (CHF). Both drugs resulted in marked systemic hemodynamic improvement. Nitroprusside had a more profound effect on pulmonary artery pressure, while hydralazine produced a greater elevation in cardiac output. Significant decreases in both systemic and pulmonary vascular resistance and pulmonary capillary wedge pressure with increases in stroke volume and stroke work index were noted with both drugs. Total renal resistance decreased and renal blood flow (RBF) significantly increased with both drugs, while the distribution of cardiac output to the kidney remained depressed. Glomerular filtration rate (GFR) did not change significantly with either drug, although increases in GFR were seen in selected patients in whom RBF increased by more than 10% from control. The fraction of plasma filtered decreased toward normal with both drugs and excretion of total cations was significantly increased. These changes all represent improvements in systemic and renal hemodynamic abnormalities occurring in patients with CHF; their maintenance during long-term therapy would facilitate patient management.

This article has been cited by other articles:

				A. Al-Hesayen and J. D. Parker Impaired Baroreceptor Control of Renal Sympathetic Activity in Human Chronic Heart Failure Circulation, June 15, 2004; 109(23): 2862 - 2865. [Abstract] [Full Text] [PDF]

				M. PACKER, N. MEDINA, and M. YUSHAK Correction of Dilutional Hyponatremia in Severe Chronic Heart Failure by Converting-Enzyme Inhibition Ann Intern Med, June 1, 1984; 100(6): 782 - 789. [Abstract] [PDF]

				R. D. MAGORIEN, D. W. TRIFFON, C. E. DESCH, W. H. BAY, D. V. UNVERFERTH, and C. V. LEIER Prazosin and Hydralazine in Congestive Heart Failure: Regional Hemodynamic Effects in Relation to Dose Ann Intern Med, July 1, 1981; 95(1): 5 - 13. [Abstract] [PDF]